|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vol. 304, Issue 3, 1268-1274, March 2003
Department of Pharmaceutical Sciences, School of Pharmacy, Texas
Tech University HSC, Amarillo, Texas (D.D.A., P.R.L., K.E.R.); and
Division of Pharmaceutical Sciences, College of Pharmacy, University of
Kentucky, Lexington, Kentucky (L.P.D., P.A.C.)
Cigarette smoking is strongly implicated in the development of
cardiovascular disorders. Recently identified nicotinium analogs may
have therapeutic benefit as smoking cessation therapies but may have
restricted entry into the central nervous system by the blood-brain barrier (BBB) due to their physicochemical properties. Using the in situ perfusion technique, lobeline, choline, and nicotinium analogs were evaluated for binding to the BBB choline transporter. Calculated apparent Ki values
for the choline transporter were 1.7 µM N-n-octyl
choline, 2.2 µM N-n-hexyl choline, 27 µM N-n-decylnicotinium iodide, 31.9 µM
N-n-octylpyridinium iodide, 49 µM
N-n-octylnicotinium iodide (NONI), 393 µM lobeline,
and
1000 µM N-methylnicotinium iodide. Nicotine and
N-methylpyridinium iodide, however, do not apparently
interact with the BBB choline transporter. Given NONI's apparent
Ki value determined in this study and its
ability to inhibit nicotine-evoked dopamine release from superfused rat
brain slices, potential brain entry of NONI via the BBB choline
transporter was evaluated. [3H]NONI exhibited a BBB
transfer coefficient value of ~1.6 × 10
3 ml/s/g
and a Km of ~250 µM. Unlabeled choline
addition to the perfusion fluid reduced [3H]NONI brain
uptake. We hypothesize the N-n-octyl group on the pyridinium nitrogen of NONI facilitates brain entry via the BBB choline
transporter. Thus, NONI may have utility as a smoking cessation agent,
given its ability to inhibit nAChRs mediating nicotine-evoked dopamine
release centrally, and to be distributed to brain via the BBB choline transporter.
This article has been cited by other articles:
![]() |
P. Ganas and R. Brandsch Uptake of L-nicotine and of 6-hydroxy-L-nicotine by Arthrobacter nicotinovorans and by Escherichia coli is mediated by facilitated diffusion and not by passive diffusion or active transport Microbiology, June 1, 2009; 155(6): 1866 - 1877. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. A. F. Albayati, L. P. Dwoskin, and P. A. Crooks Pharmacokinetics of the Novel Nicotinic Receptor Antagonist N,N'-Dodecane-1,12-diyl-bis-3-picolinium Dibromide in the Rat Drug Metab. Dispos., October 1, 2008; 36(10): 2024 - 2029. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. P. Dwoskin, T. E. Wooters, S. P. Sumithran, K. B. Siripurapu, B. M. Joyce, P. R. Lockman, V. K. Manda, J. T. Ayers, Z. Zhang, A. G. Deaciuc, et al. N,N'-Alkane-diyl-bis-3-picoliniums as Nicotinic Receptor Antagonists: Inhibition of Nicotine-Evoked Dopamine Release and Hyperactivity J. Pharmacol. Exp. Ther., August 1, 2008; 326(2): 563 - 576. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. R. Lockman, V. K. Manda, W. J. Geldenhuys, R. K. Mittapalli, F. Thomas, Z. F. Albayati, P. A. Crooks, L. P. Dwoskin, and D. D. Allen Carrier-Mediated Transport of the Quaternary Ammonium Neuronal Nicotinic Receptor Antagonist N,N'-Dodecylbispicolinium Dibromide at the Blood-Brain Barrier J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 244 - 250. [Abstract] [Full Text] [PDF] |
||||